The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Benralizumab for the Prevention of COPD Exacerbations
Open accessAbstract
BACKGROUND: The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known. METHODS: In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. <220 per cubic millimeter]) who had frequent exacerbations despite receiving guideline-based inhaled treatment. Patients were randomly assigned to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter or greater. Safety was also assessed. RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in the 30-mg benralizumab group, 1.03 per year (95% CI, 0.90 to 1.19) in the 100-mg benralizumab group, and 1.24 per year (95% CI, 1.08 to 1.42) in the placebo group; the rate ratio as compared with placebo was 0.96 for 30 mg of benralizumab (P = 0.65) and 0.83 for 100 mg of benralizumab (P = 0.05). In TERRANOVA, the estimates of the annualized exacerbation rate for 10 mg, 30 mg, and 100 mg of benralizumab and for placebo were 0.99 per year (95% CI, 0.87 to 1.13), 1.21 per year (95% CI, 1.08 to 1.37), 1.09 per year (95% CI, 0.96 to 1.23), and 1.17 per year (95% CI, 1.04 to 1.32), respectively; the corresponding rate ratios were 0.85 (P = 0.06), 1.04 (P = 0.66), and 0.93 (P = 0.40). At 56 weeks, none of the annualized COPD exacerbation rate ratios for any dose of benralizumab as compared with placebo reached significance in either trial. Types and frequencies of adverse events were similar with benralizumab and placebo. CONCLUSIONS: Add-on benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo among patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of 220 per cubic millimeter or greater (Funded by AstraZeneca [GALATHEA and TERRANOVA] and Kyowa Hakko Kirin [GALATHEA]; GALATHEA and TERRANOVA ClinicalTrials.gov numbers, NCT02138916 and NCT02155660.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,830
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Development and first validation of the COPD Assessment Test
Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W.-H., & Kline Leidy, N. (2009) · European Respiratory Journal · doi:10.1183/09031936.00102509 · Cited by 3,198
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
General considerations for lung function testing
Miller, M. R., Crapo, R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., Grinten, C. P. M. V. D., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034505 · Cited by 2,026
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
Self-citationFitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Self-citationPascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C., & Pavord, I. D. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00106-x · Cited by 743
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 625
Self-citationBafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Self-citationKolbeck, R., Kozhich, A., Koike, M., Peng, L., Andersson, C. K., Damschroder, M. M., Reed, J. L., Woods, R., Dall'Acqua, W. W., Stephens, G. L., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.004 · Cited by 586
Self-citationEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Siva, R., Green, R. H., Brightling, C. E., Shelley, M., Hargadon, B., McKenna, S., Monteiro, W., Berry, M., Parker, D., Wardlaw, A. J., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00146306 · Cited by 453
Self-citationBafadhel, M., Peterson, S., De Blas, M. A., Calverley, P. M., Rennard, S. I., Richter, K., & Fagerås, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30006-7 · Cited by 442
Self-citationSputum Eosinophilia Predicts Benefit from Prednisone in Smokers with Chronic Obstructive Bronchitis
PIZZICHINI, E., PIZZICHINI, M. M. M., GIBSON, P., PARAMESWARAN, K., GLEICH, G. J., BERMAN, L., DOLOVICH, J., & HARGREAVE, F. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.5.9804028 · Cited by 399
Brightling, C. E., Bleecker, E. R., Panettieri, R. A., Bafadhel, M., She, D., Ward, C. K., Xu, X., Birrell, C., & van der Merwe, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70187-0 · Cited by 315
Self-citationHAJIRO, T., NISHIMURA, K., TSUKINO, M., IKEDA, A., KOYAMA, H., & IZUMI, T. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.4.9802091 · Cited by 255
Yun, J. H., Lamb, A., Chase, R., Singh, D., Parker, M. M., Saferali, A., Vestbo, J., Tal-Singer, R., Castaldi, P. J., Silverman, E. K., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.04.010 · Cited by 249
Self-citationInhaled corticosteroids in COPD: friend or foe?
Agusti, A., Fabbri, L. M., Singh, D., Vestbo, J., Celli, B., Franssen, F. M. E., Rabe, K. F., & Papi, A. (2018) · European Respiratory Journal · doi:10.1183/13993003.01219-2018 · Cited by 229
Self-citationMiravitlles, M., Worth, H., Soler‐Cataluña, J. J., Price, D., Benedetto, F. D., Roche, N., Godtfredsen, N. S., van der Molen, T., Löfdahl, C., Padullés, L., et al. (2014) · Respiratory Research · doi:10.1186/preaccept-1114873655135960 · Cited by 178
Acute Exacerbations and Respiratory Failure in Chronic Obstructive Pulmonary Disease
MacIntyre, N., & Huang, Y. C. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200707-088et · Cited by 159
Leidy, N. K., Murray, L. T., Monz, B. U., Nelsen, L. M., Goldman, M. A., Jones, P., Dansie, E. J., & Sethi, S. (2014) · Respiratory Research · doi:10.1186/s12931-014-0124-z · Cited by 129
Self-citationSafety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
Jackson, D. J., Korn, S., Mathur, S. K., Barker, P. N., Meka, V. G., Martin, U. J., & Zangrilli, J. (2020) · Drug Safety · doi:10.1007/s40264-020-00926-3 · Cited by 93
Self-citationBlood eosinophil count and exacerbation risk in patients with COPD
Kerkhof, M., Sonnappa, S., Postma, D. S., Brusselle, G., Agustí, A. G. N., Anzueto, A. R., Jones, R. C. M., Papi, A. A., Pavord, I. D., Pizzichini, E., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00761-2017 · Cited by 89
Self-citationSymptomatic burden of COPD for patients receiving dual or triple therapy
Chen, S., Small, M., Lindner, L., & Xu, X. P. (2018) · International Journal of COPD · doi:10.2147/copd.s163717 · Cited by 42
Cigarette smoke-induced lung inflammation in COPD mediated via CCR1/JAK/STAT /NF-κB pathway
Zhao, K., Dong, R., Yu, Y., Tu, C., Li, Y., Cui, Y., Bao, L., & Ling, C. (2020) · Aging · doi:10.18632/aging.103180 · Cited by 32
Zhu, J., Mallia, P., Footitt, J., Qiu, Y., Message, S. D., Kebadze, T., Aniscenko, J., Barnes, P. J., Adcock, I. M., Kon, O. M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.03.021 · Cited by 25
Self-citationBiologics for Chronic Obstructive Pulmonary Disease: Present and Future
Singh, D., & Martin, U. J. (2018) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0032 · Cited by 3
Self-citationChen, R., Wang, K., Meng, X., et al. (2020) · Medicine · doi:10.1097/md.0000000000020241 · Cited by 1
Cited by
Chronic obstructive pulmonary disease
Christenson, S. A., Smith, B. M., Bafadhel, M., & Putcha, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00470-6 · Cited by 1,219
Self-citationBiologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Self-citationDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Cole, J., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303951 · Cited by 521
Self-citationAirway inflammation in COPD: progress to precision medicine
Brightling, C., & Greening, N. (2019) · European Respiratory Journal · doi:10.1183/13993003.00651-2019 · Cited by 419
Self-citation
Metadata
- Authors
- Criner, G. J., Celli, B. R., Brightling, C. E., Agusti, A., Papi, A., Singh, D., Sin, D. D., Vogelmeier, C. F., Sciurba, F. C., Bafadhel, M., Backer, V., Kato, M., Ramírez-Venegas, A., Wei, Y.-F., Bjermer, L., Shih, V. H., Jison, M., O’Quinn, S., Makulova, N., Newbold, P., Goldman, M., & Martin, U. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-12
- Volume
- 381
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2946719800
- Cited by
- 351
- References
- 30
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.